Form Type: 4/A

Accession Number:	0001562180-21-007900
Date:	2021-12-06
Issuer:	HEALTH CATALYST, INC. (HCAT)
Original Submission Date:	2021-12-07

Reporting Person:

HORSTMEIER PAUL
C/O HEALTH CATALYST, INC.
10897 SOUTH RIVER FRONT PARKWAY, #300 SOUTH JORDAN, UT 84095

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of Security	Transaction Date	2a. Deemed Execution Date	Transaction Code	Shares	Acquired or Disposed	Price per share	5. Amount of Securities Beneficially Owned Following Reported Transaction	6. Ownership Form Direct or Indirect	Nature of Indirect Ownership
COMMON STOCK	2021-12-06		M	6,063	a	$15.84	105,243	direct
COMMON STOCK	2021-12-06		S	600	d	$37.97	104,643	direct
COMMON STOCK	2021-12-06		S	2,674	d	$38.76	101,969	direct
COMMON STOCK	2021-12-06		S	2,789	d	$39.89	99,180	direct

Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security	Conversion or Exercise Price of Derivative Security	Transaction Date	Deemed Execution Date	Transaction Code	Number of Derivative Securities Acquired (A) or Disposed of (D)	Date Exercisable	Expiration Date	Title and Amount of Securities Underlying Derivative Security	Price of Derivative Security	Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY)	15.84	2021-12-06	deemed execution date	M	6,063 (d)		2029-02-05	common stock 6,063	$15.84	52,028	direct

Footnotes
ID	footnote
f1	due to a technical and administrative error, the original form 4, filed on december 7, 2021, incorrectly reflected a sale of shares of common stock by the reporting person attributed to a vesting of restricted stock units. we were recently made aware that the reporting person exercised options and sold shares from that option exercise. the exercise of those options and sale of shares is correctly reflected herein and the correct ownership tabulations are also included herein.
f2	the sale reported on this form 4 was made pursuant to a written trading plan adopted by the reporting person on december 15, 2020, in accordance with rule 10b5-1.
f3	represents the weighted average sale price of the shares sold ranging from $37.47 to $38.43 per share, inclusive.
f4	represents the weighted average sale price of the shares sold ranging from $38.47 to $39.24 per share, inclusive.
f5	represents the weighted average sale price of the shares sold ranging from $39.66 to $40.22 per share, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5).
f6	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on february 5, 2023.

Elevate your investments